23:41 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
23:55 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Dental

INDICATION: Dental Patient sample and rat studies suggest promoting reactive oxygen species (ROS) production with Feraheme ferumoxytol and hydrogen peroxide could help treat dental caries (tooth decay). In Streptococcus mutans biofilms cultured on enamel-like hydroxyapatite, Feraheme,...
16:06 , May 4, 2018 |  BC Week In Review  |  Financial News

Refuge raises $25M series B

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million on May 2 in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean...
14:42 , May 2, 2018 |  BC Extra  |  Financial News

Refuge raises $25M series B

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Fund...
13:38 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Selecta reports additional Phase II data for gout combo

Selecta Biosciences Inc. (NASDAQ:SELB) reported additional data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered...
16:51 , Apr 2, 2018 |  BioCentury  |  Finance

Maintaining Moderna

A rumored dual listing on the Hong Kong stock exchange and NASDAQ could enable Moderna Therapeutics Inc. to maintain its ballooning valuation as it enters the public market. The mRNA play has raised $1.6 billion...
17:17 , Mar 30, 2018 |  BC Week In Review  |  Company News

Therapure Biopharma spins out Evolve Biologics

Therapure Biopharma Inc. (Mississauga, Ontario) spun out its plasma products and technology division as Evolve Biologics Inc. (Mississauga, Ontario). Evolve emerges with PlasmaCap EBA technology which is used to improve the yields of plasma-based proteins....
21:26 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Selecta's gout combo lacks longer-term efficacy in Phase II trial

Selecta Biosciences Inc. (NASDAQ:SELB) reported updated data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered...
01:10 , Sep 16, 2017 |  BioCentury  |  Finance

Local leverage

What began as a fund designed to provide Eli Lilly and Co. access to innovation in China has evolved into an independent VC with a focus on innovative Chinese healthcare companies and U.S. biotechs looking...
19:48 , Sep 8, 2017 |  BC Week In Review  |  Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...